ASPCF News and Press, Acerus Pharmaceuticals Corp From 05/14/21

Acerus Pharmaceuticals Corporation (ASPCF) Q1 2021 Results Conference Call May 13, 2021 10:00 AM ET Company Participants Bob Motz - CFO Ed Gudaitis - President and CEO Conference Call Participants Presentation Operator Good morning, ladies and gentlemen, and welcome to the Q1 2021 Conference ...

TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2021. Unless otherwise noted, all amounts are in US d...

TORONTO, May 10, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that it has entered into a three-year agreemen...

TORONTO, May 06, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2021 financial and operating results on Thursday, May 13, 2021 before the market opens. The company will also host a conference call on Thursday, May 13, 2021 ...

TORONTO, April 30, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility...

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today a...

TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a speciality pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today ...

Acerus Pharmaceuticals ([[ASPCF]]) announces that it has entered into an amended agreement related to its existing credit facility with SWK Funding, a subsidiary of SWK Holdings Corporation ([[SWKH]] -2.1%).The amendments set principal repayment at $1.1M for May 15, 2021 followed by quarterly...

TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today announced that it has entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“...

Acerus Pharmaceuticals Corporation (ASPCF) Q4 2020 Earnings Conference Call March 11, 2021 10:00 ET Company Participants Bob Motz - Chief Financial Officer Ed Gudaitis - President & Chief Executive Officer Conference Call Participants Presentation Operator Good morning, ladies and gentlem...